The new oral anticoagulants continue to gain additional indications from the FDA. Earlier today Boehringer Ingelheim announced that the FDA had approved Pradaxa (dabigatran) for the treatment of venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).
…
Click here to read the full post on Forbes.
This drug is indicated for these patients who have been treated with a parenteral (injectable) anticoagulant for five to 10 days, as well as to reduce the risk of recurrent DVT and PE in patients who have been previously treated.